Parker Waichman LLP

Invokana Carries Risk of Lower Limb Amputation

Invokana May Increase Risk of Lower Limb Amputations. Regulators in the United Kingdom are warning that Invokana (canagliflozin), a type 2 diabetes medication manufactured by Johnson & Johnson subsidiary Janssen, may carry an increased risk of lower limb amputations. Similar warnings were recently issued by the European Medicines Agency (EMA) and the U.S. Food and […]

Invokana May Increase Risk of Lower Limb Amputations.

Regulators in the United Kingdom are warning that Invokana (canagliflozin), a type 2 diabetes medication manufactured by Johnson & Johnson subsidiary Janssen, may carry an increased risk of lower limb amputations. Similar warnings were recently issued by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).

Parker Waichman LLP has decades of experience representing clients in product liability and personal injury litigation. The firm continues to offer free legal consultations to individuals with questions about filing an Invokana lawsuit.

Invokana is part of a class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. These medications lower blood sugar, in combination with diet and exercise, by causing more glucose to be released in the urine.

On Mar. 22, 2017, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) warned that Invokana may be associated with an increased risk of lower limb amputation. The updated prescribing information describes amputations as an uncommon side effect, occurring in fewer than 10 patients per 1,000.

Healthcare Professionals to Monitor Invokana patients at risk for amputation

The UK regulators advise healthcare professionals to monitor Invokana patients at risk for amputation. These includes individuals with poor control of diabetes and cardiovascular problems. If patients develop foot problems such as skin infection, ulcers, osteomyelitis or gangrene, healthcare professionals should consider stopping the medication.

The MHRA announcement comes after a similar warning from the EMA, who said the increased risk may affect Invokana and other SGLT2 inhibitors. The possible increased rates of amputation mostly affect the toes, the regulatory agency said.

In a statement released in February, the EMA advised “Patients taking these medicines are reminded to check their feet regularly and follow their doctor’s advice on routine preventative foot care. They should also tell their doctor if they notice any wounds or discoloration, or if their feet are tender or painful,”

SGLT2 inhibitors include drugs such as: AstraZeneca’s Ebymect (dapagliflozin /metformin), Edistride (dapagliflozin), Xigduo (dapagliflozin/metformin) and Forxiga (dapagliflozin), Janssen Pharmaceuticals’ Invokana (canagliflozin) and Vokanamet (canagliflozin /metformin), Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and Boehringer’s Synjardy (empagliflozin /metformin).

“An increase in lower limb amputations has not been seen in studies with other medicines in the same class, dapagliflozin and empagliflozin. However, data available to date are limited and the risk may also apply to these other medicines,” EMA stated.

“The incidences of lower limb amputation given above for both CANVAS and CANVAS-R are based on interim data, and final incidence rates will depend on analysis of the final study datasets,”

FDA Places Boxed Warning on Invokana, Invokamet for Leg and Foot Amputations

Invokana Risk of Limb Amputation

Invokana Carries High Risk of Lower Limb Amputation

 

The FDA has also updated the label on Invokana and Invokamet warning about the risk of leg and foot amputations. The diabetes drugs will have a new boxed earning, the most serious type of warning, disclosing this information. Regulators announced the label update on May 16, 2017. The FDA, EMA and MHRA announced these updates following data from two large clinical trials: CANVAS (Canagliflozin Cardiovascular Assessment Study) and CANVAS-R (A Study of the Effects of Canagliflozin on Renal Endpoints in Adult Participants with Type 2 Diabetes Mellitus).

Participants in the trial were twice as likely to suffer from leg and foot amputations when taking Invokana compared to those taking a placebo.

Regulators said data showed that canagliflozin users were twice as likely to suffer from leg and foot amputations compared to those taking a placebo. In the CANVAS trial, the risk of amputation over a year period was equivalent to 5.9 out of every 1,000 patients taking canagliflozin. Comparatively, the risk was 2.8 out of every 1,000 patients taking a placebo.

Amputations mostly affected the toe and the middle of the foot, the FDA said. In some cases, however, the leg was amputated. Leg amputations occurred both above and below the knee. Some patients had more than one amputation. The agency said patients often experienced lower limb infections, gangrene, diabetic foot ulcers and ischemia prior to amputation. Patients were more likely to undergo amputations if they had amputations previously.

Data from the CANVAS-R trial also documented a higher risk of lower limb amputations among canagliflozin users compared to those taking a placebo. Over a year period, the risk of amputation with canagliflozin was 7.5 out of every 1,000 patients compared to 4.2 out of every 1,000 taking a placebo. Nearly 6,000 patients were treated with canagliflozin in both trials. The study was limited to patients with cardiovascular disease or cardiovascular risk factors other than type 2 diabetes. The boxed warning, however, is addressed to all Invokana and Invokamet users regardless of cardiovascular risk.

Patients should speak to their healthcare professional immediately if they develop the following symptoms:

  • New pain or tenderness
  • Sores or ulcers
  • Infections of the legs or feet

Patients should not stop taking their diabetes medication without first speaking to their healthcare professional.

The agency advised doctors to consider whether patients have an increased risk of amputations prior to prescribing Invokana or Invokamet. Risk factors include a prior amputation, peripheral vascular disease, neuropathy and diabetic foot ulcers. Canagliflozin treatment should be discontinued if patients develop these symptoms, the FDA says.

Last May, the FDA announced that interim data suggested an increased risk of leg and foot amputations, mostly affecting the toes among Invokana and Invokamet users. Regulators said they were investigating the issue. The boxed warning is an update on this previous communication.

Regulators state that Invokana is associated with other adverse events, including low blood pressure, ketoacidosis, kidney problems, high blood potassium, serious urinary tract infections, low blood sugar when taken with other diabetes drugs, bone breaks and increased cholesterol.

Parker Waichman notes that Invokana lawsuits are currently being filed over ketoacidosis, a condition where the blood becomes too acidic.

Need Legal Help Regarding Invokana?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).

 

Our Invokana injury attorney is here to help you when you need it the most.

Invokana Carries High Risk of Lower Limb Amputation
What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Positive: Professionalism , Quality , Responsiveness
Jairo Blanco
2 years ago
5 Star Reviews 150
Michele J has such a great personality and is very knowledgeable. She’s a great asset!!! The Long family is appreciative of her hard work on our case. I would surely recommend Parker Waichman to everyone I know.
Christipher Long
5 years ago
5 Star Reviews 150
Great staff extremely helpful and sympathetic to your needs
David Fritzman
5 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038